Lantheus to be Acquired by Curium for $102.50 Per Share Plus Contingent Payments

Lantheus Holdings, Inc. (LNTH) has entered into a definitive merger agreement to be acquired by Curium US Holdings LLC. Under the terms of the agreement, Lantheus shareholders will receive $102.50 in cash plus one Contingent Value Right (CVR) per share, representing a potential total consideration of up to $114.50 per share.

Key Details

• Merger Consideration: Shareholders will receive $102.50 in cash and one non-tradeable CVR per share upon closing.
• Contingent Value Rights (CVR): The CVR entitles holders to receive up to an additional $12.00 per share in cash, contingent upon achieving specific aggregate sales milestones for Lantheus's Global Prostate Cancer Diagnostics, Global Neurology Diagnostics, and Global DEFINITY franchises through fiscal year 2030.
• Agreement & Conditions: The agreement was signed on August 3, 2026. The transaction is not subject to a financing condition but requires shareholder approval and the satisfaction of customary closing conditions, including regulatory approvals.
• Post-Transaction: Upon completion, Lantheus will become a wholly owned subsidiary of Curium, and its common stock will be delisted from the Nasdaq Global Market.